Vaccine Info

Malaria Vaccines

Authored by
Last reviewed
November 26, 2021
Fact checked by
Robert Carlson, MD

Malaria Vaccines and Candidates

According to the U.S. CDC, Malaria is a mosquito-borne disease caused by a parasite that can now be prevented with a new vaccine.

Malaria Vaccines

Mosquirix RTS,S/AS01 Malaria Vaccine - GSK's Mosquirix RTS, S/AS01 is a recombinant vaccine consisting of the P. falciparum circumsporozoite protein from the pre-erythrocytic stage. Mosquirix aims to trigger the immune system to defend against the first stages when the Plasmodium falciparum malaria parasite enters the human host's bloodstream through a mosquito bite and infects liver cells.

Malaria Vaccine Candidates

R21 / Matrix-M Malaria Vaccine - Serum Institute of India's R21 vaccine candidate is produced by expressing recombinant HBsAg virus-like particles in Hansenula polymorpha, comprising the central repeat and the C-terminus of the circumsporozoite protein fused to the N-terminal end of HBsAg10. 

RH5.1/AS01 Malaria Vaccine - RH5.1/AS01 is a novel recombinant malaria antigen developed at the University of Oxford.

mRNA Malaria Vaccine - Announced July 26, 2021, BioNTech wants to build on its success in COVID-19 by developing the first vaccine for malaria based on mRNA technology and aims to start clinical testing by the end of 2022 in an attempt to eradicate the mosquito-borne illness.

Malaria Vaccine News

November 18, 2021 - The Lancet published a study: Assessment of experimental malaria vaccine-induced protection in pre-exposed populations.  In the field of P falciparum malaria vaccine development, the availability of controlled human malaria infection (CHMI) model has helped to systematically select vaccine candidates, including the advanced subunit vaccines RTS,S (now recommended by WHO), R21, and the whole, live organism-based vaccine, PfSPZ Vaccine, for further clinical development.

November 17, 2021 - A presentation was given at the 70th annual meeting of the American Society of Tropical Medicine and Hygiene. This study was conducted better to characterize COVID-19 in a high malaria transmission setting and to determine the burden/describe the clinical impact of SARS-CoV-2 and malaria co-infection. Conclusion: Though Covid-19 patients with P. falciparum infection had a higher frequency of confusion and vomiting, co-infection with malaria did not seem deleterious. Low previous malaria exposure was associated with severe/critical Covid-19 and adverse outcomes.

October 29, 2021 - The World Health Organization endorsed the first-ever vaccine against malaria. This achievement is the product of 30 years of research and development. 

Clinical Trials

No clinical trials found